The effect of chronic renal failure on hepatic drug metabolism and drug disposition.
about
Toxicity of amphetamines: an updateMechanistic modelling of tesaglitazar pharmacokinetic data in subjects with various degrees of renal function--evidence of interconversion.Effect of hepatic or renal impairment on eltrombopag pharmacokinetics.Efficacy and safety of vitamin K-antagonists (VKA) for atrial fibrillation in non-dialysis dependent chronic kidney disease.Warfarin dosing in patients with impaired kidney functionEffects of chronic kidney disease on liver transport: quantitative intravital microscopy of fluorescein transport in the rat liver.Effects of serum from patients with chronic renal failure on rat hepatic cytochrome P450Influence of kidney function on risk of supratherapeutic international normalized ratio-related hemorrhage in warfarin users: a prospective cohort study.Drug development and use in the elderly: search for the right dose and dosing regimen (Parts I and II).Effect of renal impairment on the pharmacokinetics of bupropion and its metabolitesMechanistic basis of adverse drug reactions: the perils of inappropriate dose schedules.Hepatic clearance, but not gut availability, of erythromycin is altered in patients with end-stage renal disease.Effects of uremic toxins on transport and metabolism of different biopharmaceutics drug disposition classification system xenobioticsKidney function influences warfarin responsiveness and hemorrhagic complications.Clinical review: Drug metabolism and nonrenal clearance in acute kidney injury.Hemodialysis does not alter in vitro hepatic CYP3A4 and CYP2D6 metabolic activity in uremic serum.Pharmacokinetics of dolutegravir in HIV-seronegative subjects with severe renal impairment.Pharmacokinetics in special populations.Using drug probes to monitor hepatic drug metabolism in critically ill patients: midazolam, a flawed but useful tool for clinical investigation of CYP3A activity?Renal clearance in drug discovery and development: molecular descriptors, drug transporters and disease state.Modeling and predicting drug pharmacokinetics in patients with renal impairment.Effects of chronic kidney disease and uremia on hepatic drug metabolism and transport.Consequences of renal failure on non-renal clearance of drugs.Renal Targeted Therapies of Antihypertensive and Cardiovascular Drugs for Patients With Stages 3 Through 5d Kidney Disease.Downregulation of hepatic acetylation of drugs in chronic renal failure.Pharmacokinetics and pharmacodynamics of orally administered ruxolitinib (INCB018424 phosphate) in renal and hepatic impairment patients.Pharmacokinetics of the novel oral prostacyclin receptor agonist selexipag in subjects with hepatic or renal impairment.Inhibitory effects of uraemic toxins 3-indoxyl sulfate and p-cresol on losartan metabolism in vitro.Acute kidney injury reduces the hepatic metabolism of midazolam in critically ill patients.Pharmacokinetics of alpha-lipoic acid in subjects with severe kidney damage and end-stage renal disease.Inhibition of human drug-metabolising cytochrome P450 and UDP-glucuronosyltransferase enzyme activities in vitro by uremic toxins.Conjugated metabolites represent the major circulating forms of Abelmoschus manihot in vivo and show an altered pharmacokinetic profile in renal pathology.Pharmacokinetics of the Novel Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone (BAY 94-8862) in Individuals With Renal Impairment.Evaluation of warfarin dose requirements in patients with chronic kidney disease and end-stage renal disease.
P2860
Q22252794-7631160D-2E32-4E95-A2F2-B5AC262DE8DFQ31147512-4A375B93-1B36-4DB6-B5A4-8E9C261332F9Q33391009-39D5168B-34B4-4578-9744-1AA86E78E801Q33589886-54EAAD50-2C12-43CA-9E4F-EAA2B9EA661AQ34238435-044262CF-0870-449F-B625-49886DA5BF0DQ34726696-993BB4A9-CD5D-4D16-AF97-9E67908C44AFQ35048793-E81219C5-C36E-40E0-9D65-199BD2D4E863Q35553851-DCE0F57D-00DF-4AA7-9E84-A1E8ED3DBA85Q35826495-D13B787B-606E-4C5E-B7D2-5887C83A8F7BQ36024598-9B3762A4-7B7D-4A7D-A1E1-1836A31724D8Q36040772-C6FD4353-1999-4378-8772-F9C54263962CQ36634909-071837EA-E870-46E5-BEF6-DF02714E3B74Q36634986-F8D75AC7-27BB-47F4-806C-C52FB0800BDDQ37146449-FA198690-B0E6-4F26-853D-C201F7F6517FQ37336958-75DA4A6D-32F1-4CFD-93EC-B60F92A563FEQ37391009-75B73C8D-2B95-4F6B-947C-1BF92901FBA5Q37469818-48D2B7F1-E15E-4AE1-AC30-BA01D30B6176Q37550561-332D3C78-40B2-4956-ABA3-3BAC1621EA8BQ37733572-3C2CCEA0-B061-4F81-9FCE-5072A276A5ABQ37740151-2A0B9278-14E8-4889-997E-FC8BE2F0C968Q37960638-01FBE108-1D43-41E1-A70F-07786AAC2203Q38153196-B61446F9-CE61-4270-A26E-2A08D070F550Q38214827-A1791644-0B95-444C-9411-23842C09FED7Q38739039-B92CDFDD-CD04-47AD-AA74-C0698DABA39CQ39588785-0D31A56E-AA34-40ED-A383-26A2845459B5Q39810667-FED45DA6-7B1A-4393-A5B6-08BA485E1FA0Q42282811-718A63A2-B7E7-40BD-8378-55AFCF3C650DQ42932513-5CE2C633-8C19-4BCF-826C-3F4C3948F10AQ43488121-0EC5C72D-53A9-4222-9A83-30A2C151F7ECQ45259348-B2A770FD-5863-4AC7-97FA-CD13CD5068FDQ47853973-63F52A59-DCF0-430B-B50F-3E28AADED0C1Q51842797-271ACAC3-0CAD-497C-B38B-A587254D921BQ53059504-7BBBB965-43B3-4DDD-873D-D656B0B217DEQ53089586-BF9F9C64-0DB2-406A-8CE3-9FC12234276C
P2860
The effect of chronic renal failure on hepatic drug metabolism and drug disposition.
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
The effect of chronic renal failure on hepatic drug metabolism and drug disposition.
@ast
The effect of chronic renal failure on hepatic drug metabolism and drug disposition.
@en
type
label
The effect of chronic renal failure on hepatic drug metabolism and drug disposition.
@ast
The effect of chronic renal failure on hepatic drug metabolism and drug disposition.
@en
prefLabel
The effect of chronic renal failure on hepatic drug metabolism and drug disposition.
@ast
The effect of chronic renal failure on hepatic drug metabolism and drug disposition.
@en
P2860
P1433
P1476
The effect of chronic renal failure on hepatic drug metabolism and drug disposition.
@en
P2093
Albert W Dreisbach
Juan J L Lertora
P2860
P356
10.1046/J.1525-139X.2003.03011.X
P577
2003-01-01T00:00:00Z